Nuvalent Announces "OnTarget 2026" Operating Plan and Key An

Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , San Francisco , California , United States , Alexandra Balcom , James Porter , Prnewswire Nuvalent Inc , Nasdaq , Exchange Commission , Nuvalent Inc , Healthcare Conference , Chief Executive Officer , New Drug Application , Chief Financial Officer , Global Registrational , First Pivotal , First Approved , Send Cash , Private Securities Litigation Reform Act , Quarterly Report , Region ,